Arbor Biotechnologies
- 09/11/2021
- Series B
- $215,000,000
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.
- Industry Biotechnology Research
- Website https://arbor.bio/
- LinkedIn https://www.linkedin.com/company/arborbio/about/
Related People
Devyn SmithFounder
Devyn joined Arbor in April, 2021 as Chief Executive Officer and board member. He also serves as Vice Chairman of the Alliance for Regenerative Medicine (ARM) and advises multiple biotech companies. Previously, Devyn was Chief Operations Officer and Head of Strategy at Sigilon Therapeutics, a clinical stage biotechnology company based in Cambridge, MA from 2017 to 2021.
Prior to this he was head of Business Operations and Strategy at the Medicinal Sciences Division at Pfizer R&D. He was previously at Pfizer's Neusentis Research Unit in the UK from 2011 as Chief Operating Officer responsible for strategy and operations for the unit. Neusentis was focused on developing assets for pain and sensory disorders as well as developing the Regenerative Medicine portfolio. He joined Pfizer's Strategic Management Group in August 2009 supporting the head of Pharmatherapeutics R&D on developing and implementing business strategies and operational plans as well as the Regenerative Medicine Research Unit in its strategic work.
Prior to joining Pfizer, Smith was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge). In his consulting experience, he led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies. Regenerative Medicine has been an area of strong focus with over 30 engagements, several published papers, and numerous invited conference presentations. Prior to joining The Frankel Group, Smith worked as a management consultant at Adventis Corporation focused on clients in information intensive companies.
Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University. He is currently an adjunct faculty member at Northeastern University.